Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response’s determination and listed label supports for cardiovascular disorder risk and probable dementia, with breast cancer and endometrial cancer context, are directly supported by the provided FDA label excerpts (Boxed Warning and Warnings/Precautions; supporting WHI/WHIMS data).
Category Scores
Accurate Statements
Boxed Warning states estrogen plus progestin therapy should not be used for prevention of cardiovascular disease or dementia.
Boxed Warning text: “should not be used for the prevention of cardiovascular disease or dementia”.
Boxed Warning and label support increased risk of developing probable dementia with estrogen plus progestin therapy (WHIMS).
Boxed Warning text: “WHI Memory Study (WHIMS)… increased risk of developing probable dementia…”, and Warnings 5.3 excerpts.
Boxed Warning/label support increased risk of invasive breast cancer with estrogen plus progestin therapy (WHI substudy).
Boxed Warning text: “increased risk of invasive breast cancer…”, and Warnings 5.2 excerpts.
Boxed Warning/label context supports increased risk of endometrial cancer and that adding a progestin reduces endometrial hyperplasia risk.
Boxed Warning text: “There is an increased risk of endometrial cancer…” and Warnings 5.2 excerpts.
Warnings and Precautions 5.1 describes increased risk of pulmonary embolism, DVT, stroke, and myocardial infarction with estrogen plus progestin therapy.
5.1 Cardiovascular Disorders excerpt: “increased risk of pulmonary embolism, deep vein thrombosis (DVT), stroke and myocardial infarction…”.
Clinical studies (WHI/WHIMS) provide the referenced cardiovascular outcome and probable dementia risk findings for CE+MPA vs placebo.
14.6 WHI substudy outcomes and 14.7 WHIMS probable dementia relative and absolute risk excerpts.
Unsupported Statements
Contradictions
Important Omissions
No details were provided regarding specific contraindications or management steps (e.g., discontinuation instructions) tied to cardiovascular events; however, the AI response was focused on label support for the risk/boxed warning claim rather than contraindications.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response only asserts that the risk-related claims are supported by the FDA label and cites relevant label sections/excerpts; it does not provide dosing or clinical decision guidance.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Limited inclusion of detailed label management wording (e.g., discontinuation instructions) since the response was primarily a support/evidence summary.
Suggested Improvement
When summarizing label alignment for safety claims, also capture any explicit management/next-step statements present in the relevant warnings (e.g., discontinue immediately if stroke/VTE occurs), if the user’s question requires them.